BioNTech Slashes 1,860 Jobs in Retreat From Pandemic-Era Manufacturing
Published on 09/29/2026 at 06:20 | Editorial boerse-global.de
BioNTech is dismantling the bulk of the vaccine production network it built during the COVID-19 boom, a restructuring that will cost as many as 1,860 jobs worldwide and hand the company's pandemic-era manufacturing legacy to its partner Pfizer. The Mainz-based firm confirmed that its plants in TĂĽbingen, Marburg and Idar-Oberstein will be wound down in stages, alongside a facility in Singapore, after an exhaustive search for industrial buyers came up empty.
The staged shutdowns begin with TĂĽbingen at the end of 2027. Marburg follows in early 2028, and production at Idar-Oberstein is scheduled to run out by the end of 2028. The company said it has reached agreements with works councils covering socially compatible arrangements and additional severance payments.
Not everything went to the scrapheap. JPT Peptide Technologies, a Berlin subsidiary with roughly 130 employees, was sold to Dubag. The larger production sites, however, found no takers — a stark illustration of how far global demand for mRNA manufacturing capacity has fallen since the pandemic's peak. Lingering overcapacity and a cooling market for COVID-19 shots scuppered any hoped-for sale to contract manufacturers.
A €500 Million Lifeline for the Cancer Pipeline
Management expects the pullback from in-house production to deliver recurring annual savings of around €500 million, with the benefit flowing from 2029. That cash is earmarked for clinical development of cancer medicines, part of a broader push to concentrate resources and reduce reliance on pandemic revenue.
Should investors sell immediately? Or is it worth buying BioNTech?
The financial backdrop explains the urgency. BioNTech posted a net loss of €1.35 billion for the first half of 2026, widening sharply from a deficit of €802.4 million a year earlier. Heavy research and development spending continues to weigh on the balance sheet, though the company still held roughly €16.6 billion in cash and securities at the end of June.
Founders Prepare to Hand Over the Keys
Running parallel to the structural overhaul is a generational change at the top. Co-founders Ugur Sahin and Ă–zlem TĂĽreci intend to leave BioNTech by the end of 2026 at the latest to build a new venture. Leadership is to pass to Oelkers by no later than 1 February 2027, with the incoming chief executive tasked with executing the oncology strategy.
Delaware Court Keeps Patent Suit Alive
Legal pressure is mounting on another front. A federal judge in the US state of Delaware declined a request from Pfizer, BioNTech and Moderna to dismiss patent claims brought by Bayer and Monsanto. The dispute centres on mRNA stabilisation techniques that Bayer says were originally developed in the 1980s for plant research. The court ruled that at this early stage of proceedings neither patent invalidity nor non-infringement had been sufficiently established, meaning the case will proceed. No verdict on an actual patent violation has been reached.
Shares closed yesterday at €87.25, leaving the stock up 7.2% since the start of the year. Investors took the news broadly in stride. For a company still trading in positive territory year-to-date, the plant closures read less as a retreat than as a deliberate clearing of the decks — shedding costly pandemic-era capacity to fund the transition from COVID-19 winner to focused oncology specialist. The loss of hundreds of manufacturing jobs is a bitter pill for those affected, but the market's gaze has already shifted to the pipeline and the €500 million a year that will help finance it.
Ad
BioNTech Stock: New Analysis - 29 September
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
